Skip to main content
Fig. 2 | BMC Microbiology

Fig. 2

From: Intra-wound vancomycin powder for the eradication of periprosthetic joint infection after debridement and implant exchange: experimental study in a rat model

Fig. 2

The serum α1-AGP during the whole experiment (pre-operation, days 14 and 28). Control (no antibiotics); SV: Systemic vancomycin (intraperitoneal injection, 88 mg/kg, every 12 h); VP: Intra-wound vancomycin powder (before closure of the capsule, 88 mg/kg, single dosage); SV&VP: Systemic vancomycin & intra-wound VP (intraperitoneal injection, 88 mg/kg, every 12 h; combined with intra-wound VP before closure of the capsule, 88 mg/kg, single dosage). **P < 0.01 (Compared with Control group), ##P < 0.01 (Compared with VP group), ∆P < 0.01 (Compared with SV group). n = 8

Back to article page

BMC Microbiology

ISSN: 1471-2180

Contact us